Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by β-amyloid25-35 injection into Meynert basal nuclei of rats)

Bulletin of Experimental Biology and Medicine

Volumn 146, Issue 1, 2008, Pages 77-80

  Ostrovskaya, R U ^a   Belnik, A P ^a   Storozheva, Z I ^b  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

^b P K ANOKHIN INSTITUTE OF NORMAL PHYSIOLOGY   (Russian Federation)

Author keywords

amyloid(25 35); Alzheimer disease model; Meynert giant cell nucleus; Noopept

Indexed keywords

AMYLOID BETA PROTEIN; GVC 111; NOOPEPT; NOOTROPIC AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; MALE; MEMORY DISORDER; MEYNERT BASAL NUCLEUS; NEUROPROTECTION; NONHUMAN; PASSIVE AVOIDANCE; RAT; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BASAL NUCLEUS OF MEYNERT; DIPEPTIDES; DISEASE MODELS, ANIMAL; HUMANS; MALE; MEMORY DISORDERS; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; RANDOM ALLOCATION; RATS; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 58049153117     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-008-0211-6     Document Type: Article

References (14)

1. L. P. Kovalenko, M. G. Miramedova, S. V. Alekseeva, et al., Eksp. Klin. Farmakol., 65, No. 2, 53-55 (2002).
2. R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, et al., Ibid., No. 5, 66-72.
3. R. U. Ostrovskaya, T. Kh. Mirzoev, F. A. Firova, et al., Ibid., 64, No. 2, 11-14 (2001).
4. K. S. Us, P. M. Klodt, V. S. Kudrin, et al., Neirokhimiya, 23, No. 2, 122-126 (2006).
5. J. Y. Ban, S. O. Cho, S. Y. Jeon, et al., Neurosc. Lett., 420, No. 2, 184-188 (2007).
6. J. V. Bukanova, E. I. Solntseva, and V. G. Skrebitsky, Int. J. Neuropsychopharmacol., 5, 229-237 (2002).
7. Q. S. Chen, B. L. Kagan, Y. Hirakura, et al., J. Neurosci. Res., 60, No. 1, 65-72 (2000).
8. L. Giovannelli, F. Casamenti, C. Scali, et al., Neuroscience, 66, No. 4, 781-792 (1995).
9. T. A. Gudasheva, T. A. Voronina, R. U. Ostrovskaya, et al., Eur. J. Med. Chem., 31, No. 2, 151-157 (1996).
10. T. Harkany, S. O'Mahony, J. P. Kelly, et al., Behav. Brain Res., 90, 133-145 (1998).
11. M. Q. Liao, Y. J. Tzeng, L. Y. Chang, et al., FEBS Lett., 581, No. 6, 1161-1165 (2007).
12. R. U. Ostrovskaya, M. A. Gruden, N. A. Bobkova, et al., J. Psychopharmacol., 21, 611-619 (2007).
13. A. Pealsman, C. Hoyo-Vadillo, S. B. Seredenin, et al., Int. J. Dev. Neurosci., 21, 117-124 (2003).
14. Z. I. Storozheva, A. T. Proshin, V. V. Sherstnev, et al., BMC Pharmacol., 8, No. 1-49 (2008).